iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight